Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE . Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 1985; 312: 692–700.

    Article  Google Scholar 

  2. O’Reily SE, Klimo P, Connors JM . The evolving role of etoposide in the management of lymphoma and Hodgkin’s disease. Cancer 1991; 67: 271–280.

    Article  Google Scholar 

  3. Weiss RB. In: Perry MC (ed). The Chemotherapy Source Book, 2nd edn. Lippincott Williams and Wilkins: Baltimore, MD, USA, 1996, pp 613-634.

    Google Scholar 

  4. Chen YB, Lane AA, Logan BR, Zhu X, Akpet G, Aljurt MD et al. Impact of conditioning regiment on outcomes for patient with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1046–1053.

    Article  Google Scholar 

  5. Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 971–983.

    Article  Google Scholar 

  6. Siderov J, Prasad P, del Boer R, Desai J . Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86: 12–13.

    Article  CAS  Google Scholar 

  7. Kasperek C, Black CD . Two case of suspected immunological-based hypersensitivity reaction to etoposide therapy. Ann Pharmacother 1992; 26: 1227–1230.

    Article  CAS  Google Scholar 

  8. Schacter L . Etoposide phosphate: what, why, where and how? Semin Oncol 1996; 23 (Suppl 13):1–7.

    CAS  PubMed  Google Scholar 

  9. Biljana L, Vera M, Marina D, Sanja M, Katerina J, Zlatko H . Hypersensitivity to etoposide in case of metastatic choriocarcinoma. Case Rep Oncol 2013; 6: 490–492.

    Article  Google Scholar 

  10. Castells M . Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6: 476–481.

    Article  CAS  Google Scholar 

  11. Mariana C, del Carmen Sancho-Serra M, Maria S . Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012; 61: 1575–1584.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Polistena.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polistena, P., Tran, Q., Cirillo, M. et al. Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma. Bone Marrow Transplant 52, 455–456 (2017). https://doi.org/10.1038/bmt.2016.288

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.288

This article is cited by

Search

Quick links